Integral Diagnostics Azione

Integral Diagnostics P/E Forward

Il Rapporto P/E Prospettico di Integral Diagnostics (IDX.AX) al 16 ago 2026 è 191,42. L'anno precedente, Rapporto P/E Prospettico era -14,74 — una variazione del -1398,93% (superiore).

P/E Forward

191,42

YoY

-1398,93%

Ultimo aggiornamento:

Rapporto P/E Prospettico di Integral Diagnostics ammonta a 2026 191,42 . Rapporto P/E Prospettico di Integral Diagnostics ammontava a 2025 -14,74 . Diminuisce del -1398,93% superiore rispetto all'anno precedente.
Access this data via the Eulerpool API

Integral Diagnostics Analisi delle Azioni

Cosa fa Integral Diagnostics? Integral Diagnostics Ltd is an Australian company that has been providing medical imaging services for over 25 years. The company was founded in 1994 by Dr. Ian Kadish and a team of radiologists in Perth, Western Australia, offering radiology services to local clinics and hospitals. Over the years, Integral Diagnostics has expanded its services to provide imaging services nationwide. The business model of Integral Diagnostics is to deliver medical imaging to enable doctors and their patients to have a fast and accurate diagnosis. The company offers imaging services for a variety of medical specialties, including radiology, cardiology, obstetrics and gynecology, and neurology. They operate over 49 locations in Australia, many of which are in rural areas where access to medical care may be limited. Integral Diagnostics offers a wide range of products based on medical imaging. These include X-rays, mammography, ultrasound, CT scans, MRI scans, PET scans, and bone density scans. The company takes pride in being one of the few Australian medical imaging companies to offer a complete range of imaging services. Their services are conducted by qualified radiologists specialized in interpreting medical images. Integral Diagnostics also operates clinics for performing diagnostic and therapeutic procedures such as biopsies, drainages, and injections. These procedures are carried out by highly qualified radiologists to provide patients with faster and more accurate diagnoses. Integral Diagnostics is committed to quality assurance and has a comprehensive quality management system that is annually reviewed by independent auditors. The company is accredited by both the Australian Medical Association and the Australian National Accreditation Scheme (NATA). These accreditations recognize the high standards that Integral Diagnostics sets for delivering medical imaging services. One of Integral Diagnostics' recent activities is their use of artificial intelligence (AI) in image interpretation. The company has partnered with MaxQ AI, a leading provider of AI solutions for medical imaging. Through this partnership, Integral Diagnostics doctors can utilize the latest AI tools to improve their patients' diagnoses. Integral Diagnostics is a strong advocate for social justice and is dedicated to supporting disadvantaged communities in Australia. The company has partnered with nonprofit organizations such as the National Breast Cancer Foundation, The Smith Family, and the Friendship Foundation. Overall, Integral Diagnostics has undergone impressive growth over the past 25 years and is now a leading Australian medical imaging company. With a wide range of imaging services and a strong focus on quality and social responsibility, the company is well-positioned to continue its success in the future. Integral Diagnostics è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su Integral Diagnostics azioni

Rapporto P/E Prospettico di Integral Diagnostics è 191,42 nel 2026.

Il Rapporto P/E Prospettico di Integral Diagnostics è passato da -14,74 a 191,42, con una variazione del -1398,93 %. Il valore è superiore rispetto all'anno precedente.

Su Eulerpool è possibile consultare lo sviluppo storico completo del Integral Diagnostics di Rapporto P/E Prospettico dal 2006, con valori annuali, grafici e analisi dettagliate.

Il P/E prospettico utilizza i guadagni futuri stimati per valutare un'azione. Un P/E prospettico inferiore rispetto al P/E storico suggerisce che gli analisti prevedono crescita degli utili.

Per valutare di Rapporto P/E Prospettico, è essenziale confrontarlo con i competitor nello stesso settore e industria. Su Eulerpool puoi trovare confronti diretti con l'industria per Rapporto P/E Prospettico.

Un 'buono' varia a seconda del settore e della fase di sviluppo dell'azienda. Su Eulerpool puoi confrontare Integral Diagnostics di Rapporto P/E Prospettico con i competitor del settore e la media industriale per valutare se è attraente.

Access this data via the Eulerpool API

Valutazione — Integral Diagnostics

Tutte le Metriche Finanziarie — Integral Diagnostics